BMO Capital Starts ObsEva (OBSV) at Outperform

BMO Capital initiates coverage on ObsEva (NASDAQ: OBSV) with a Outperform rating and a price target of $23.00.

Analyst Do Kim comments "We believe OBE2109 has the best drug profile among GnRH antagonists, which should enable it to take meaningful market share in uterine fibrosis and endometriosis, despite Elagolix's three-year lead time. We also believe OBE2109's predictable impact on estradiol (E2) levels will allow dosing with or without add-back therapy, providing another advantage over competitors. We consider Nolasiban underappreciated, despite positive Phase 3 data and a clear opportunity in IVF. Live birth results in 4Q18 could have investors reassessing Nolasiban. We assign no value for OBE022 in preterm labor, which could provide additional upside."

For an analyst ratings summary and ratings history on ObsEva click here. For more ratings news on ObsEva click here.

Shares of ObsEva closed at $14.62 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Citi Resumes Sherwin-Williams (SHW) at Buy
• BTIG Upgrades Medtronic, Inc. (MDT) to Buy